Fuji Pharma Co., Ltd. · TSE:4554
Fuji Pharma — Q2 FY9/2025 Earnings Presentation
38 slides from Fuji Pharma's earnings presentation, May 14, 2025
Slide 1: FY9/25 2Q Investor Meeting Materials
FY9/25 2Q Investor Meeting Materials May 14 , 2025 Fuji Pharma Co., Ltd. TSE Prime：4554
Slide 2: Topics for this meeting
Topics for this meeting FY9/25 2Q (1H) operating profit increased 59.6% YoY. Growth in profit was underpinned by an increase in sales of newly launched products and acquired products, and improved gross profit margins due to a favorable product mix The attainment rate was 92.1% for net sales and
Slide 3: Agenda
Agenda 01 FY9/25 2Q (1H) Consolidated Financial Summary 02 FY9/25 2Q (1H) Review and 2H Initiatives 03 FY9/25 Full-year Earnings Forecast 04 Focus Business Topics 05 Q&A Appendix 2
Slide 4: FY9/25 2Q (1H) Consolidated Financial Summary
01 FY9/25 2Q (1H) Consolidated Financial Summary
Slide 5: First half Consolidated Financial Highlights
FY9/25 First half Consolidated Financial Highlights FY9/24 1H FY9/25 1H YoY FY9/25 VS 1H Forecast FY9/25 （JPY million） Actual Actual （Ratio） Plan （Ratio） Plan Net Sales 21,388 24,095 +2,707 26,150 ▲2,055 53,360 +12.7% ▲7.9% Gross Profit 8,233 9,889 +1,656 - - 21,670 +20.1% Operating Profit 1,443 2,3
Slide 6: First half Consolidated Financial Summary
FY9/25 First half Consolidated Financial Summary Women’s Health : While products such as F-meno® Capsules, Alyssa® Combination Tablet, and Favoir® Tablets Net Sales contributed, progress has been delayed. Biosimilar : Contribution from USTEKINUMAB BS Syringe CMO : Growth led by OLIC Others :
Slide 7: First half Sales by Segment
FY9/25 First half Sales by Segment The three growth strategies of the mid-term Business plan — Women's Healthcare, Biosimilars, and Global CMO — are progressing steadily. FY9/23 1H FY9/24 1H FY9/25 1H YoY Change （JPY million） Actual Actual Actual （Ratio） Women’s Healthcare 8,402 9,675 10,278 +6.2% （
Slide 8: First half Sales and Full-year Progress of Strategic Products
FY9/25 First half Sales and Full-year Progress of Strategic Products Products FY9/23 1H FY9/24 1H FY9/25 1H YoY FY9/25 Field Category note (JPY million) Actual Actual Actual Amount Ratio Plan Progress Menopausal disorder F-meno® Capsules Brand 918 1,267 1,802 535 42.2% 3,700 48.7％ Market share conti
Slide 9: First half Consolidated (YoY Comparison)
FY9/25 First half Consolidated (YoY Comparison) （JPY million） Net Sales Operating Profit 8
Slide 10: First half Consolidated Results vs. Forecast
FY9/25 First half Consolidated Results vs. Forecast （JPY million） Net Sales Operating Profit 9
Slide 11: First half Overview
FY9/25 First half Overview Net Sales JPY 24,095 million (up 12.6% YoY, an increase of JPY 2,707 million) • Women’s healthcare, newly launched products and acquired products contributed • Delays in progress on several strategic products Operating Profit JPY 2,304 million (up 59.7% YoY, an increase of
Slide 12: FY9/25 2Q (1H) Review and 2H Initiatives
02 FY9/25 2Q (1H) Review and 2H Initiatives
Slide 13: 1H Factors Behind Sales Unachieved and Responses
FY9/25 1H Factors Behind Sales Unachieved and Responses State of Breakdown of Factors Behind Unachieved Sales Responses Measures UTROGESTAN: Share defense with thorough follow-up of priority Impact of the resumption of competitor product supply facilities In progress Structural Factors LEVONORGE
Slide 14: Alyssa Combination Tablet
Alyssa® Combination Tablet (Estetrol (E4)/Drospirenone (DRSP) Combination Tablet) Treatment of dysmenorrhea LEP market The LEP market is expanding with a CAGR of 18.3% from 2019 to 2024*2 Of patients treated for dysmenorrhea in Japan, 81%*1 are using LEPs (low-dose estrogen/progesterone preparat
Slide 15: Delivering Alyssa to a broad age range
Delivering Alyssa to a “broad age range” Building on Recognized Safety to Implement Additional Measures efficacy and tolerability Marked novelty Acclaimed safety Marked novelty Current Next steps First new type of estrogen in around 50 years state From promotion focused on E₄ (safety) features t
Slide 16: FY9/25 Full-year Earnings Forecast
03 FY9/25 Full-year Earnings Forecast
Slide 17: Full-year Consolidated Earnings Forecast
FY9/25 Full-year Consolidated Earnings Forecast The full-year forecast remains unchanged from the initial forecast, due to strengthening of sales activities and optimization of expenses during 2H, as well as the expectation of a lump-sum income from contracts Both net sales and operating profit
Slide 18: Toward Achieving the FY9/25 Full-year Plan
Toward Achieving the FY9/25 Full-year Plan Positive factors • Alyssa : The number of prescribed patients has been increasing since March 2025 • Impact of drug price revision : The drug price revision in April 2025 will have a smaller impact than assumed at the beginning of the period (-2% to -1.1% a
Slide 19: Shareholder Returns
FY9/25 Shareholder Returns Introduction of progressive dividend policy Payout ratio 30% based on NOPAT 32.9% Dividend per share（JPY）｜ Payout ratio（％） 38.4% 41.5% 32.7% 33.6% 16.8% 50 32.4% 50.0% 43.3% 45.5 30.6% 33.5% 31.5% 26.2% 42.5 3.0 26.5% 40 24.0% 32.0% 37 40.0% 29.9% 35 24.9% 21.8% 22.5 2
Slide 20: Focus Business Topics
04 Focus Business Topics ihe. {sail
Slide 21: Four Growth Strategies and Three Initiatives to Realize Vision 2035
Four Growth Strategies and Three Initiatives to Realize Vision 2035 Vision 2035 Always focusing on creating new value to women's healthcare and contributing to society where everyone can enjoy well-being Medium-term growth drivers Long-term growth driver Greater contributions Expansion of the Growth
Slide 22: Expanding Biosimilars market, our strength in partnering with Alvotech
Expanding Biosimilars market, our strength in partnering with Alvotech Market The global biosimilars market is growing at a CAGR of +9.6% and is expected to grow to US$12,540 million by 2024 (approx. ¥1.8 trillion market) In Japan, the role of biosimilars is expanding as a trump card for optimiz
Slide 23: Aiming for First-to-Market Launch with Three Pipeline Products
Aiming for First-to-Market Launch in a JPY 160 Billion Market with Three Pipeline Products Biosimilar pipeline FY9/24 FY9/25 FY9/26 FY9/27 FY9/28 FY9/29 Three Products Filed for Approval in September–October 2024 Filgrastim Launched in May 2013 Three New BS Products Filed and Preparing for Launc
Slide 24: Closing Summary
Closing Summary FY9/25 2Q (1H) operating profit increased 59.6% YoY. Growth in profit was underpinned by an increase in sales of newly launched products and acquired products, and improved gross profit margins due to a favorable product mix The attainment rate was 92.1% for net sales and 96.8% f
Slide 25: Q&A
05 Q&A
Slide 26: Appendix
Appendix ihe. {sail
Slide 27: First half Consolidated Financial Summary
FY9/25 First half Consolidated Financial Summary FY9/24 FY9/25 YoY Change FY9/25 VS Plan Progress 1H 1H Amount Ratio Plan (JPY million) Ratio Net Sales 21,388 24,095 2,707 12.7% 53,360 45.2% Gross Profit 8,233 9,889 1,656 20.1% 21,670 45.6% Gross Margin 38.5% 41.0% - - 40.6% - SG&A Expenses 6,789 7,
Slide 28: Previous results contributed to sales
FY9/25 Previous results contributed to sales Newly launched products FY9/25 January 2024: LENALIDOMIDE capsules “F” +JPY billion in Sales February 2024: LANDIOLOL HYDROCHLORIDE “F” May 2024: Ustekinumab BS (biosimilar), Sugammadex intravenous infusion “F” Newly approved products FY9/24 New
Slide 29: Consolidated earnings forecast; Net sales
FY9/25 Consolidated earnings forecast ; Net sales Net sales increased by JPY 7.2 billion Women's Healthcare and Other Businesses compared to the previous fiscal year. were major growth drivers. （JPY million） +3,269 53,360 ＋728 46,138 +3,024 +204 Biosimilar CMO Others Women’s healthcare FY9/24 24/9期
Slide 30: Four Growth Strategies and Three Initiatives to Realize Vision 2035
Four Growth Strategies and Three Initiatives to Realize Vision 2035 Vision 2035 Always focusing on creating new value to women's healthcare and contributing to society where everyone can enjoy well- being Long-term growth Medium-term growth drivers driver Greater Expansion of the Growth in the Strat
Slide 31: Women's Healthcare (Domestic) – Menopause Treatment
Women's Healthcare (Domestic) – Menopause Treatment Diverse range of Vasomotor symptoms (hot flashes, rush of blood, sweating, coldness, etc.), mental symptoms (irritability, anxiety, insomnia, depression, lethargy) menopausal Joint and other symptoms (back pain, joint pain, stiff shoulders), dizzin
Slide 32: Women's Healthcare (Domestic) – Menopause Treatment
Women's Healthcare (Domestic) – Menopause Treatment Market Menopausal Drug Sales Trends More than 12 million women have menopausal symptoms*1 Sales of the strategic product F-meno (progesterone) was up 42% YoY Adoption rate of HRT increased from 1.8% to 2.5%*2 Sales of L’estrogel (estrogen)
Slide 33: Women's Healthcare (Overseas): OLIC Pharma Business
Women's Healthcare (Overseas): OLIC Pharma Business (Manufacturing and Sales Division) Oral contraceptive Nextstellis® Estetrol (E4)/Drospirenone (DRSP) combination *Alyssa® Combination Tablet in Japan In Thailand, the Combination Tablet will be marketed by group company OLIC as oral contraceptive
Slide 34: Sales by Former Field
Reference Sales by Former Field Medical Field Category FY9/23 FY9/24 FY9/25 YoY First half First half First half Amount Ratio （JPY million） Actual Actual Actual Acute Medical Care 7,284 8,139 8,436 297 3.6% Women's Healthcare 8,091 9,266 9,950 684 7.4% CMO Business (OLIC) 1,965 1,943 2,172 229 11.8%
Slide 35: Impact of Drug price revisions
Impact of Drug price revisions Drug price revision on rate(Drug cost base) Our drug price revision rate Due to the mid-year drug price revision conducted this fiscal year, no industry average is available. 34
Slide 36: Reference information link
Reference information link Long-term Vision for 2035 （October 2, 2024） https://www.fujipharma.jp/english/__upload/9676557bd1299efed3deb75e21ea400d2180476e.pdf New Mid-Term Business Plan FY9/2025-FY9/2029 （Explained on November 26, 2024） https://www.fujipharma.jp/english/__upload/EN_MidtermBusinessPl
Slide 37: Disclaimer regarding forecasts and projections
Disclaimer regarding forecasts and projections The financial forecast and other projections included in this presentation reflect our judgement based on the information available at the time of its preparation, and therefore they contain potential risks and uncertainties. Actual results may vary fro
Slide 38: Fuji Pharma
Fuji FZ; Pharma